CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗儿童白血病
英文原题：Chimeric antigen receptor T cell therapy in childhood leukaemia.
查看英文原题
Chimeric antigen receptor T cell therapy in childhood leukaemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种有前景的过继性细胞疗法。该过程重新改造患者来源的T细胞，使其表达一种靶向选定肿瘤表达抗原的杂合受体。针对CD19抗原的CAR-T 细胞疗法在其他治疗失败的血液系统恶性肿瘤中取得了高度成功，尤其是复发性B细胞急性淋巴细胞白血病（B-ALL）。本综述聚焦于使用CD19靶向CAR-T 细胞疗法治疗儿童B-ALL的众多真实世界方面。我们讨论了临床医生的一些考虑因素，包括生产时间、给药及接受这种新型疗法患者的护理、毒性和结局。我们还讨论了许多医生现在面临的治疗不确定性，即在患者治疗历程中何时使用CAR-T 细胞疗法，尤其是在考虑造血干细胞移植时。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy is a promising form of adoptive cell therapy. This process re-engineers patient-derived T cells to express a hybrid receptor targeting a selected tumour-expressed antigen. CAR T cell therapy directed against the CD19 antigen has been highly successful in haematological malignancies that have failed other therapies, particularly relapsed B-cell acute lymphoblastic leukaemia (B-ALL). This review focuses on the numerous real-world aspects of treating children with B-ALL with CD19-targeted CAR T cell therapy.
We discuss some of the considerations for clinicians including manufacturing time, administration and care of the patient receiving this novel therapy, toxicities and outcomes.
We also discuss the therapeutic uncertainty many physicians now face of when to use CAR T cell therapy in the patient journey, especially when haematopoietic stem cell transplant is being considered.
论文信息
- 作者
- Wang SS、Abbott RC、Gilsenan M、Duke T、Khaw SL
- 单位
- Children's Cancer Centre, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia shiqistacie.wang@rch.org.au.Australia
- 文献类型
- 综述
- 期刊
- Archives of disease in childhood2025 Jun 19
- 原文标识
- PubMed 39914887 · DOI 10.1136/archdischild-2024-328263